Takeda blood disorder therapy Adzynma linked to patient death: FDA
Source: SeekingAlpha
2025-11-21 11:02:36 ET
More on Takeda Pharmaceutical
- Takeda Pharmaceutical Company Limited (TAK) Q2 FY2025 Earnings Call Transcript
- Takeda Pharmaceutical Company Limited FY2025 Q2 - Results - Earnings Call Presentation
- Takeda Pharmaceutical Company Limited (TAK) Discusses Global Strategic Collaboration for Next-Generation Oncology Assets and ADC Molecules Transcript
- Takeda Pharmaceutical Non-GAAP EPS of ¥279.00, revenue of ¥2219.5B; updates FY outlook
- Innovent inks $11.4 billion cancer drug partnership with Japan's Takeda
Read the full article on Seeking Alpha
For further details see:
Takeda blood disorder therapy Adzynma linked to patient death: FDA
Takeda Pharmaceutical Company Limited American Depositary Shares
NASDAQ: TAK
TAK Trading
0.17% G/L:
$17.85 Last:
1,296,138 Volume:
$17.92 Open:
TAK Latest News
March 02, 2026 02:00:00 am
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
February 24, 2026 09:35:00 am
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
TAK Stock Data
$57,107,745,653
3,115,826,299
N/A
157
N/A
Pharmaceuticals
Healthcare
JP
Chuo-ku
